Jonathan Aschoff
Stock Analyst at Roth Capital
(0.46)
# 4,040
Out of 4,941 analysts
44
Total ratings
23.08%
Success rate
-35.83%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTRK Ontrak | Maintains: Buy | $4 → $3 | $0.44 | +581.82% | 3 | Jul 9, 2025 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $1.75 | +528.79% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $11.76 | +78.57% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $2.06 | +287,278.64% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.47 | +1,124.49% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $4.99 | +14,208.62% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.70 | +2,761.23% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $5,040 → $2,640 | $9.29 | +28,317.65% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.66 | +5,941.38% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $4.61 | +18,121.26% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $10.15 | +254.68% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,750 → $18,000 | $5.90 | +304,984.75% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.80 | +417.24% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $3.70 | +5,305.41% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.30 | +508.70% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $2.42 | +892,461.98% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.03 | +676.70% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $3.09 | +3,141.49% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.93 | +42,910.75% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $4.62 | +722.51% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360,000 | $4.06 | +8,866,895.07% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.49 | +6,342.95% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.39 | +443.93% | 1 | Dec 19, 2019 |
Ontrak
Jul 9, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.44
Upside: +581.82%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $1.75
Upside: +528.79%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $11.76
Upside: +78.57%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $2.06
Upside: +287,278.64%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.47
Upside: +1,124.49%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $4.99
Upside: +14,208.62%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.70
Upside: +2,761.23%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $5,040 → $2,640
Current: $9.29
Upside: +28,317.65%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.66
Upside: +5,941.38%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $4.61
Upside: +18,121.26%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $10.15
Upside: +254.68%
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $5.90
Upside: +304,984.75%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $5.80
Upside: +417.24%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $3.70
Upside: +5,305.41%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.30
Upside: +508.70%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $2.42
Upside: +892,461.98%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.03
Upside: +676.70%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $3.09
Upside: +3,141.49%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.93
Upside: +42,910.75%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $4.62
Upside: +722.51%
Feb 12, 2021
Initiates: Buy
Price Target: $360,000
Current: $4.06
Upside: +8,866,895.07%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.49
Upside: +6,342.95%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $2.39
Upside: +443.93%